The list:
- Plavix (BMY) — $1.62 billion in sales
- Nexium (AZN) — $1.40 billion
- Ability (Otsuka) — $1.34 billion
- Singulair (MRK) — $1.24 billion
- Seroquel (AZN) — $1.16 billion
- Advair Diskus (GSK) — $1.14 billion
- Crestor (AZN) — $1.12 billion
- Cymbalta (LLY) — $1.03 billion
- atorvastatin (generic) — $0.95 billion
- Humira (ABT) — $0.93 billion
The biggest gain compared to the fourth quarter of 2011 went to the atorvastatin generic, which saw sales rise by nearly $450,000. The generic has drawn sales from Lipitor, made by Pfizer Inc. (NYSE: PFE), which lost patent protection last year. Lipitor sales fell by more than $760,000 in the quarter to just over $840,000.
A generic version of Plavix — clopidogrel — recently hit the market, so the top of the rankings may be in for a change later this year.
Paul Ausick
Top Gaining Stocks
Top Losing Stocks